Skip to content

Remote Ischemic Conditioning in Patients Undergoing Primary Percutaneous Coronary Intervention

Impact of Remote Ischemic Conditioning in Patients Undergoing Primary Percutaneous Coronary Intervention

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07272408
Enrollment
2
Registered
2025-12-09
Start date
2022-09-01
Completion date
2023-12-30
Last updated
2025-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Conditioning, Primary Percutaneous Coronary Intervention, Remote

Brief summary

This study aimed to detect the effects of remote ischemic conditioning on infarct size, global contractility, morbidity, mortality, and renal function in patients undergoing primary percutaneous coronary intervention.

Detailed description

Myocardial infarction (MI) generally refers to segmental (regional) myocardial necrosis, typically endocardial in location, secondary to occlusion of an epicardial artery. Primary percutaneous coronary intervention (PPCI) is a reperfusion therapy that is carried out in patients who usually have ST-segment elevation MI (STEMI) within a specific time window. During ischemia, metabolic acidosis occurs due to anaerobic metabolism, and ischemic injury ensues. After restoration of blood supply, reactive oxygen species (ROS) production and local inflammation increase secondary injury.

Interventions

PROCEDURERemote ischemic conditioning

Remote ischemic conditioning (RIC) was applied to those patients.

PROCEDURENormal primary percutaneous coronary intervention

Patients followed the standard primary percutaneous coronary intervention pathway.

Sponsors

Helwan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age more than 18 and less than 75 years old. * Both sexes. * Patients with new ST-segment elevation at the J-point in V1:V6 leads with the cut-point: ≥ 1mm other than leads V2-V3 where the following cut-points apply: ≥ 2mm in men ≥ 40 years; ≥ 2.5mm in men \< 40 years, or ≥ 1.5mm in women regardless of age. * Patients with new left bundle branch block (LBBB).

Exclusion criteria

* ST-segment elevation myocardial infarction (STEMI) with cardiogenic shock. * Severe comorbidities (uncontrolled hypertension, morbid obesity, recent cerebrovascular stroke, respiratory failure, sepsis, and stage 4 & 5 malignancy). * End-stage renal disease on hemodialysis. * Previous coronary artery bypass graft surgery (CABG). * Myocardial infarct within the previous 30 days. * Multi-vessel coronary artery disease. * Failure of culprit vessel recanalization. * Conditions precluding use of remote conditioning ie: paresis of upper limb. * Life expectancy of less than 1 year due to a non-cardiac pathology. * Patients who receive nephrotoxic drugs such as non-steroidal anti-inflammatory drugs and aminoglycosides.

Design outcomes

Primary

MeasureTime frameDescription
Cardiac death1 month post-procedureIncidence of cardiac death was recorded.

Secondary

MeasureTime frameDescription
Hospitalization for heart failure1 month post-procedureHospitalization for heart failure post-randomization in the intention-to-treat population was assessed.
Contrast induced nephropathy1 month post-procedureContrast induced nephropathy was assessed.
Incidence of adverse events1 month post-procedureIncidence of adverse events was recorded.
Renal impairment1 month post-procedureRenal impairment was recorded.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026